Pfizer reports positive data from late-stage BEACON CRC trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Results from the phase III BEACON CRC trial show significant improvements in overall survival and objective response rates for the BRAFTOVI Triplet and BRAFTOVI Doublet combination (BRAFTOVI and cetuximab), compared to cetuximab plus irinotecan-containing regimens (Control), and provide analysis of the efficacy and safety of the BRAFTOVI Triplet compared to the BRAFTOVI Doublet.

The trial evaluates the combination of Braftovi (encorafenib), Mektovi (binimetinib), and cetuximab (Braftovi Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer, following one or two lines of therapy.

Pfizer sponsors the trial.

BRAFTOVI Triplet showed a median OS of 9.0 months, compared to 5.4 months for Control. An improved ORR of 26% was observed in BRAFTOVI Triplet compared to 2% for Control.

These data were presented Sept. 30 at ESMO.

The company expects to submit the results of the trial for marketing approval in the United States in Q4 2019.

Table of Contents

YOU MAY BE INTERESTED IN

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 
On Feb. 3, the House of Representatives passed the Senate Amendment to H.R. 7148, the Consolidated Appropriations Act, 2026, by a vote of 217 to 214. Later that day, President Donald Trump signed the bill into law, officially ending the brief partial government shutdown that began on Jan. 31. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login